Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074878 · ClinicalTrials.gov registry record · Phase 1
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
A Phase 1 study, sponsored by Mothaffar Rimawi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02074878: Clinical Trial Phase 1 study, sponsored by Mothaffar Rimawi.
NCT02074878 is a Phase 1 study that was terminated before completion, run by Mothaffar Rimawi. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02074878, a Phase 1 study, was terminated before completion, sponsored by Mothaffar Rimawi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase 1 Trial. Crizotinib is a medication that is taken by mouth. It has shown that it can help slow down or stop the growth of tumor cells. The marketing name of the drug is "Xalkori". It has been approved by the FDA (Food and Drug Administration) to treat other types of metastatic cancer, but the investigators believe it may be helpful to treat breast cancer as well. Sunitinib is the other medication used in the study. It is also taken by mouth in the form of a capsule. The marketing name of this drug is "Sutent". It too has been approved by the FDA to treat other types of cancer, but not for breast cancer. In this study the investigators will be combining both of these two treatments, but at different doses. One third of the patients will take Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day. One third of the patients will take Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day, and One third of the patients will take Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day.
Interventions
- DRUG Crixotinib 200 mg and Sunitinib Cohort 1
- DRUG Crixotinib 250 mg and Sunitinib Cohort 2
- DRUG Crizotinib & Sunitinib 37.5 mg Cohort 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02074878
The ClinicalTrials.gov registry entry for NCT02074878 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mothaffar Rimawi, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Crixotinib 200 mg and Sunitinib Cohort 1 is the first listed.
NCT02074878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02074878 about?
NCT02074878 is a clinical study titled "CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer". This is a Phase 1 Trial. Crizotinib is a medication that is taken by mouth. It has shown that it can help slow down or stop the growth of tumor cells. The marketing name of the drug is "Xalkori". It has been approved by the FDA (Food and Drug Administration) to treat other types of metastatic cancer...
What is the current status of trial NCT02074878?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-06. Estimated completion is 2017-05-16.
What interventions are being tested in trial NCT02074878?
The interventions under investigation include: Crixotinib 200 mg and Sunitinib Cohort 1 (DRUG), Crixotinib 250 mg and Sunitinib Cohort 2 (DRUG), Crizotinib & Sunitinib 37.5 mg Cohort 3 (DRUG).
Who is sponsoring clinical trial NCT02074878?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.